Co-Diagnostics (HAM:C970) Other Financing: €0.01 Mil (TTM As of Mar. 2026)


HAM:C970 Co-Diagnostics Inc HAM:C970
60 GF Score
Price €5.55
GF Value €3.83
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Other Financing?

Co-Diagnostics HAM:C970 60 Other Financing is €0.01 Mil as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 60/100 and a GF Value™ of €3.83. The stock has 6 warning signs investors should review.

Co-Diagnostics's Other Financing for the three months ended in Mar. 2026 was €0.00 Mil.

Co-Diagnostics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01 Mil.

Co-Diagnostics Other Financing Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Other Financing Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.17 0.00 0.00 0.01

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.01 0.00
HAM:C970
60GF Score
Co-Diagnostics Inc HAM:C970
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.01 Mil mean?
Co-Diagnostics (HAM:C970) has a Other Financing of €0.01 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Co-Diagnostics and its competitors.
Is Co-Diagnostics' Other Financing too high?
Co-Diagnostics' current Other Financing is €0.01 Mil. Overall, Co-Diagnostics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Other Financing compare to ALRTF and SINT?
Co-Diagnostics' Other Financing of €0.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Co-Diagnostics and its competitors. Co-Diagnostics's current Other Financing is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Other Financing of €0.01 Mil. The stock's GF Value™ is €3.83, compared to a current price of €5.55 — trading 44.9% above its estimated fair value. The current Other Financing is €0.01 Mil. Co-Diagnostics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Other Financing is €0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 44.9% above its estimated GF Value™ of €3.83.

Key valuation signals for HAM:C970:

  • Other Financing: €0.01 Mil
  • GF Value™: €3.83 vs. price of €5.55 (44.9% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
60GF Score

Get the complete analysis for HAM:C970

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€3.83
GF Value